SCHEMBL25651297

SCHEMBL25651297

CC(C)c1ccccc1C1CN(C)CCN1C(C)(C)CC1CC1c1ccccc1C1CN(C)CCN1C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.31
HTR2A P28223 2/20 0.30
LMNA P02545 2/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
TSHR P16473 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
HTR3E A5X5Y0 1/20 0.30
HTR3B O95264 1/20 0.30
ABCB11 O95342 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25645172 0.85 HTR2C (0.30) HTR2COPRM1OPRK1
SCHEMBL25613537 0.84 HTR2A (0.39) HSP90AA1HTR2ALMNAKDM4EMEN1
SCHEMBL24774501 0.84 HTR2A (0.39) HSP90AA1HTR2ALMNAKDM4EMEN1
SCHEMBL25651296 0.83 SLC6A2 (0.32) HTR2ASLC6A2HTR2CSLC6A4HTR2B
SCHEMBL25651325 0.81 TACR1 (0.40) KDM4EMEN1KMT2A
SCHEMBL25651272 0.78
SCHEMBL25629558 0.78 TACR1 (0.34) LMNAMEN1CYP1A2CYP3A4CYP2C9
SCHEMBL25613556 0.72 KMT2A (0.33) MEN1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL24775425 0.70 HTR2A (0.40) HTR2ALMNAKDM4EMEN1USP2
SCHEMBL24775424 0.70 HTR2A (0.40) HTR2ALMNAKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 HSP90AA1 463/4885HTR2A 1857/4885LMNA 1102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.